GlassScriptPhysician profile
Michael Disciglio
NPI 1922075373
$6,474.70
in general payments reported to CMS, 2019-2025
38 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,733 · 2020: $2,171 · 2021: $1,295 · 2022: $26.69 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,305.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $564.32 | 2019-2021 | |
| Amarin Pharma, INC. | $474.53 | 2019-2021 | |
| Amgen INC. | $412.98 | 2019-2022 | |
| Lilly USA, LLC | $333.16 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $326.03 | 2019-2021 | |
| Pfizer INC. | $285.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $283.26 | 2019-2021 | |
| Abbvie INC. | $250.13 | 2019-2022 | |
| Gilead Sciences, INC. | $249.99 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $231.20 | 2019-2021 | |
| Allergan, INC. | $165.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $160.77 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $152.25 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $140.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.63 | 2019-2020 | |
| Genentech USA, INC. | $95.80 | 2019 | |
| Eisai INC. | $82.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $77.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.79 | 2019-2020 | |
| Mannkind Corporation | $65.14 | 2019 | |
| Currax Pharmaceuticals LLC | $41.30 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $38.25 | 2019-2020 | |
| Astellas Pharma US INC | $27.15 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.55 | 2021 | |
| Tactile Systems Technology INC | $16.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.00 | 2021 | |
| Sanofi Pasteur INC. | $14.93 | 2019 | |
| Vivus LLC | $14.66 | 2019 | |
| Genzyme Corporation | $14.57 | 2021 | |
| Becton, Dickinson and Company | $14.56 | 2020 | |
| Ibsa Pharma INC. | $14.47 | 2019 | |
| Lundbeck LLC | $14.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.32 | 2020 | |
| Strongbridge US INC. | $14.19 | 2019 | |
| Horizon Therapeutics Plc | $14.17 | 2021 | |
| Acorda Therapeutics, INC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Disciglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.